These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38219961)

  • 1. Selective granulocyte-monocyte apheresis during induction with vedolizumab in moderate-severe ulcerative colitis: Experience in a tertiary hospital.
    Suárez Ferrer C; Martin-Arranz E; Martín-Arranz MD
    Gastroenterol Hepatol; 2024; 47(7):721-726. PubMed ID: 38219961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis?
    Rodríguez-Lago I; Benítez JM; Sempere L; Sáez-González E; Barreiro-de Acosta M; de Zárate JO; Cabriada JL
    J Clin Apher; 2019 Dec; 34(6):680-685. PubMed ID: 31518013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of granulocyte-monocyte apheresis and tofacitinib: Multicentre and retrospective study.
    Rodríguez-Lago I; Cañete F; Guerra-Del-Río E; Herrera-deGuise C; Iglesias E; Leo E; Zabana Y; Barreiro-de Acosta M; Ginard D; Cabriada JL
    Gastroenterol Hepatol; 2024; 47(7):727-733. PubMed ID: 38266817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis.
    Nakamura M; Yamamura T; Maeda K; Sawada T; Mizutani Y; Ishikawa E; Ohashi A; Kajikawa G; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Fujishiro M
    Intern Med; 2020 Dec; 59(23):3009-3014. PubMed ID: 32727993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA and granulocyte-monocyte adsorption apheresis combotherapy after inadequate response to anti-TNF agents in ulcerative colitis.
    Sáez-González E; Moret-Tatay I; Bastida G; Aguas M; Iborra M; Nos P; Beltrán B
    J Clin Apher; 2024 Feb; 39(1):e22101. PubMed ID: 38054256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life effectiveness and safety of vedolizumab in moderate-to-severe ulcerative colitis: A single-center experience in Northern China.
    Yan J; Ding X; Wu J; Liu A; Fang L; Xu Y
    Medicine (Baltimore); 2024 Jul; 103(27):e38759. PubMed ID: 38968537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of granulocyte and monocyte adsorption apheresis in paediatric inflammatory bowel disease: a prospective pilot study.
    Martín de Carpi J; Vilar P; Prieto G; García Novo MD; Ribes C; Varea V
    J Pediatr Gastroenterol Nutr; 2008 Apr; 46(4):386-91. PubMed ID: 18367949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyoderma gangrenosum in an ulcerative colitis patient during treatment with vedolizumab responded favorably to adsorptive granulocyte and monocyte apheresis.
    Shibuya T; Haga K; Saeki M; Haraikawa M; Tsuchihashi H; Okahara K; Nomura O; Fukushima H; Murakami T; Ishikawa D; Ikeda S; Nagahara A
    J Clin Apher; 2020 Sep; 35(5):488-492. PubMed ID: 32767842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
    Rodríguez-Lago I; Sempere L; Gutiérrez A; Núñez A; Leo Carnerero E; Hinojosa E; Mora M; Cañete F; Mañosa M; Herrera C; Beltrán B; Forés A; Arjona D; Barreiro-de Acosta M; Khorrami S; Aguirre U; Ginard D; Cabriada JL
    Scand J Gastroenterol; 2019 Apr; 54(4):459-464. PubMed ID: 30982369
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect and safety of granulocyte-monocyte adsorption apheresis for patients with ulcerative colitis positive for cytomegalovirus in comparison with immunosuppressants.
    Yoshino T; Nakase H; Matsuura M; Matsumura K; Honzawa Y; Fukuchi T; Watanabe K; Murano M; Tsujikawa T; Fukunaga K; Matsumoto T; Chiba T
    Digestion; 2011; 84(1):3-9. PubMed ID: 21311190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
    Tanaka T; Sugiyama S; Goishi H; Kajihara T; Akagi M; Miura T
    BMC Gastroenterol; 2013 Aug; 13():130. PubMed ID: 23961883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
    Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
    United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents.
    Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P
    Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study.
    Kopylov U; Verstockt B; Biedermann L; Sebastian S; Pugliese D; Sonnenberg E; Steinhagen P; Arebi N; Ron Y; Kucharzik T; Roblin X; Ungar B; Shitrit AB; Ardizzone S; Molander P; Coletta M; Peyrin-Biroulet L; Bossuyt P; Avni-Biron I; Tsoukali E; Allocca M; Katsanos K; Raine T; Sipponen T; Fiorino G; Ben-Horin S; Eliakim R; Armuzzi A; Siegmund B; Baumgart DC; Kamperidis N; Maharshak N; Maaser C; Mantzaris G; Yanai H; Christodoulou DK; Dotan I; Ferrante M
    Inflamm Bowel Dis; 2018 Oct; 24(11):2442-2451. PubMed ID: 29788318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study.
    Ueno N; Sugiyama Y; Kobayashi Y; Murakami Y; Iwama T; Sasaki T; Kunogi T; Takahashi K; Tanaka K; Ando K; Kashima S; Inaba Y; Moriichi K; Tanabe H; Taruishi M; Saitoh Y; Okumura T; Fujiya M
    BMC Gastroenterol; 2021 Aug; 21(1):316. PubMed ID: 34362299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-intensified granulocyte-monocyte apheresis in therapy refractory ulcerative colitis.
    Schultheiß C; Weischenberg R; Herrmann A; Haller B; Schmid RM; Reindl W; Huber W
    Artif Organs; 2015 Feb; 39(2):187-92. PubMed ID: 24981894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
    Dignass A; Akbar A; Baumgart DC; Bommelaer G; Bouguen G; Cadiot G; Gillessen A; Grimaud JC; Hart A; Hoque S; Makins R; Michiels C; Moreau J; Premchand P; Ramlow W; Schanz S; Subramanian S; von Tirpitz C; Bonaz B
    Scand J Gastroenterol; 2018 Apr; 53(4):442-448. PubMed ID: 29513111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with the outcomes in ulcerative colitis patients undergoing granulocyte and monocyte adsorptive apheresis as remission induction therapy: A multicenter cohort study.
    Ishiguro Y; Ohmori T; Umemura K; Iizuka M
    Ther Apher Dial; 2021 Aug; 25(4):502-512. PubMed ID: 33029920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center.
    Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL
    Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.